XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Cap 1 mRNA is immunologically silent. Cap 0 mRNA triggers innate immune sensors. Uncapped mRNA does both — without the translational efficiency advantage. The ratio of cap 1 to cap 0 to uncapped mRNA
View details → Circular RNA has no 5' cap. It has no poly(A) tail. The analytical methods validated for linear mRNA drug substance — capping efficiency by LC-MS/MS, poly(A) tail length by CGE, integrity by full-length peak
View details →
A base editor is a deaminase fused to a Cas9 nickase. A prime editor is a reverse transcriptase fused to a Cas9 nickase. Neither requires a double-strand DNA break. Neither has an approved drug
View details → Oncolytic viruses sit at an unusually demanding CMC intersection: the product must retain a defined viral identity and engineered genotype, reproduce consistently, express any therapeutic transgene as intended, demonstrate biological potency, and maintain an
View details →
Vowst received FDA approval in April 2023 — the first orally administered microbiome therapeutic for C. difficile recurrence prevention. Rebyota was approved in November 2022 as the first fecal microbiota product for rectal administration.
View details → A 3D-bioprinted scaffold delivering a drug is not a drug product with a device delivery system bolted on. It is a combination product in which the scaffold material, the fabrication process, the drug loading
View details → Every patient's neoantigen cancer vaccine has a different mRNA sequence. There is no reference standard, because the reference is the patient's own tumor mutational profile — and no two tumor mutational profiles are the
View details →
The prefilled syringe is simultaneously a container closure system and a drug delivery device. How you define it in your NDA determines the entire CMC regulatory pathway.
View details → An autoinjector that delivers 98% dose accuracy at room temperature can fail the same accuracy standard at refrigerator temperature with the identical formulation, and the physics behind that failure is entirely predictable before the
View details → Your USP <787> sub-visible particle test is compliant. Every batch passes ≥10 μm ≤6,000 and ≥25 μm ≤600 particles per container. What FDA will ask for in your BLA review, and what most biologics
View details → Your container closure system passed compatibility testing. Your stopper vendor provided a Masterfile. Your vial meets USP <660> container standards. And then CDER opens your 3.2.P.7 section and finds that your extractables study used
View details → A ready-to-use parenteral product in a pre-filled IV bag seems simpler than a vial requiring reconstitution and dilution. The bag is pre-filled, the drug is pre-dissolved, the nurse hangs it and connects the line.
View details → An implant that delivers drug for one year or three years requires an in vitro drug release test that runs for one year or three years at real-time conditions, or a validated accelerated method
View details →
When you transfer your manufacturing process into a multi-product CMO, cleaning validation stops being the CMO's general housekeeping practice and becomes a regulatory control specific to your API. The question FDA investigators ask during
View details → Supply chain redundancy is the supply chain strategy. Dual-source manufacturing is the regulatory program that makes supply chain redundancy work. The difference matters because the second source cannot supply commercial product until it is
View details → An FDA-approved NDA is not a J-NDA CMC package. The ICH CTD format is common. The regulatory expectations are not.
View details → Health Canada operates under the same ICH CTD framework and uses the same ICH guideline set as FDA. None of that means a Health Canada CTA CMC package is the same as an FDA
View details → The ICH CTD format harmonized the structure of global drug regulatory submissions. It did not harmonize what goes inside them.
View details →